Unibest

Pharmaceutical intermediates

Canagliflozin Intermediates

4 pharmaceutical intermediates for Canagliflozin. Indication: Type 2 Diabetes Mellitus; Diabetic Nephropathy.

提交项目All intermediates

About Canagliflozin

Originator
Mitsubishi Tanabe Pharma Corporation
Indication
Type 2 Diabetes Mellitus; Diabetic Nephropathy
Approved Date
03/29/2013
DS/DP
07/14/2027

Available intermediates

4 intermediates currently listed for Canagliflozin. Request specifications, documentation or a quotation for any item below.

Canagliflozin intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
2-(4-Fluorophenyl)-5-[(5-iodo-2-methylphenyl)methyl]thiophene898566-17-1//
2-(4-Fluorophenyl)-5-[(5-bromo-2-methylphenyl)methyllthiophene1030825-20-7//
2-(4-Fluorophenyl)thiophene58861-48-6//
(1S)-1,5-Anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4methylphenyl]-D-glucitol tetraacetate866607-35-4//

Other programs under C

Cabozantinib S-malateCalcipotriolCalcitriolCamlipixantCangrelor TetrasodiumCapivasertib Capmatinib HydrochlorideCarfilzomib

Building toward Canagliflozin?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →